Aldeyra Therapeutics has reported that its Phase III trial of Reproxalap, a drug for treating allergic conjunctivitis and dry-eye disease, has produced positive results. The liquid eye drop formulation of the small-molecule modulator of reactive aldehyde species demonstrated statistically significant reductions in eye itchiness across the 11 primary endpoint comparisons for patients treated with either Reproxalap or a 0.25% Reproxalap ophthalmic solution. Patients also showed a reduction in eye redness and changes in total ocular score, encompassing redness, itching, and tearing. No safety concerns were noted, and the most common adverse reaction was mild irritation at the installation site.
Reproxalap could be an alternative to over-the-counter eye drops for allergic conjunctivitis treatment and may be relevant in treating dry-eye disease. The FDA is currently reviewing the drug as a treatment for dry-eye disease with a decision expected by Nov. 23.
The announcement of positive results from their Phase III trial of Reproxalap caused Aldeyra's stock to hit a high of at